Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
A phase 2 trial of Iparomlimab and tuvonralimab in Head and neck squamous cell carcinoma, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.
Overview
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC is a phase 2 interventional study registered as NCT07447570 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with 27 participants planned, started 2025-10-15 and due to reach its primary completion in 2027-12-31. Interventions recorded: Iparomlimab and Tuvonralimab injection, Hypofractionated Radiotherapy, Chemotherapy. Conditions recorded: Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody.
Linked to the drug Iparomlimab and tuvonralimab because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer
Shares Iparomlimab and tuvonralimab and the tag pipeline.
- Triala Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy
Shares Iparomlimab and tuvonralimab and the tag pipeline.
- TrialMIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialResponse Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialFID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Shares Head and neck squamous cell carcinoma and the tag pipeline.